Masato Iida
Vice PresidentPractice Areas
Education
Ph.D., Graduate School of Agricultural and Life Sciences, The University of Tokyo
Professional Background
MSD K.K. (formerly Banyu Pharmaceutical Co., Ltd.)
Expertise
Prosecution, trials for invalidation, and suits against trial decisions
Publications
Iida, M., Matsuda, M., Komotani H., (2008) Plk3 phosphorylates topoisomerase ll alpha at Thr(1342)–a site not recognized by Plk1, Biochem J., 411(1):27-32
Iida, M., Sasaki, T., Komatani, H., (2009) Overexpression of Plk3 causes morphological change and cell growth suppression in ras pathway-activated cells, J Biochem., 146(4):501-7
Iida, M., (2016) Experimental Medicine: Supplementary Volume, Standards for mouse phenotyping, Patents and laws relating to CRISPR/Cas9, Yodosha Co., Ltd., 97-98Iida, M., (2018) Experimental Medicine, Breadth of claims related to antibody drugs as considered based on the judgment of Amgen Inc. v. Sanofi S.A., Yodosha Co., Ltd., Vol. 36, No. 9 1490-1491
Languages
English
Dr. Iida is qualified to represent parties in court in IP litigation. He specializes in biochemistry, molecular biology, and pharmaceuticals. Dr. Iida has experience constructing target screening systems and evaluation systems for anti-cancer agents (both cell-based and cell-free systems).
